Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, international, multi-center, Phase 2 study in adult patients
with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene
fusion.